About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York | 17,259 Studies Near You | Clareo Health

Clinical Trials LocationsNew York

Clinical Trials in New York

Discover 17,259 clinical trials near New York, New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4141-4160 of 17,259 trials

COMPLETEDPhase 2< 1 mile

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

NCT03117309

Phase II trial of nivolumab in 120 treatment naïve patients with ccRCC.

Advanced Renal Cell Carcinoma

Michael B. Atkins, MD164 participantsStarted Apr 2017

New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +9 more locations

Active Not RecruitingPhase 2< 1 mile

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646

The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.

Memorial Sloan Kettering Cancer Center64 participantsStarted Jul 2017

Hartford, Connecticut, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +5 more locations

Find Trials by Condition in New York

Breast Cancerin New York Lung Cancerin New York Prostate Cancerin New York Colorectal Cancerin New York Melanomain New York Leukemiain New York Lymphomain New York Pancreatic Cancerin New York Ovarian Cancerin New York Brain Cancerin New York Diabetes

Data from ClinicalTrials.govTerms

Active Not RecruitingNA< 1 mile

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

NCT02922036

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

EBR Systems, Inc.300 participantsStarted Jan 2018

Huntsville, Alabama, United States • La Jolla, California, United States • Fort Lauderdale, Florida, United States +65 more locations

Active Not RecruitingPhase 3< 1 mile

RNS System NAUTILUS Study

NCT05147571

To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.

EpilepsyIdiopathic Generalized EpilepsyGeneralized Tonic Clonic Seizure

NeuroPace100 participantsStarted Aug 2022

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Aurora, Colorado, United States +20 more locations

Active Not RecruitingPhase 3< 1 mile

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Carcinoma, Ovarian EpithelialOvarian NeoplasmsOvarian Cancer+7 more

CanariaBio Inc.615 participantsStarted Aug 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Concord, California, United States +145 more locations

TERMINATEDPhase 2/3< 1 mile

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

Dermatomyositis

Alexion Pharmaceuticals, Inc.38 participantsStarted Nov 2021

Phoenix, Arizona, United States • Irvine, California, United States • Santa Monica, California, United States +108 more locations

COMPLETED< 1 mile

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

NCT06833268

This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.

HER2-positive Breast Cancer

Daiichi Sankyo228 participantsStarted Jan 2025

New York, New York, United States

COMPLETEDPhase 3< 1 mile

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first complete remission (CR)/ complete remission with incomplete blood count recovery (CRi) following induction with or without consolidation chemotherapy. The study is amended to include an extension phase (EP). The EP allows participants who are currently receiving oral azacitidine and who are demonstrating clinical benefit as assessed by the investigator, to continue receiving oral azacitidine after unblinding by sponsor until the participant meets the criteria for study discontinuation or until oral azacitidine becomes commercially available and reimbursed. In addition, all participants in the placebo arm and participants who had been discontinued from the treatment phase (irrespective of randomization arm) and continuing in the follow-up phase will be followed for survival in the EP.

Leukemia, Myeloid, Acute

Celgene472 participantsStarted Apr 2013

Phoenix, Arizona, United States • Burbank, California, United States • Duarte, California, United States +220 more locations

COMPLETEDPhase 38.2 miles

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366

The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.

Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc.106 participantsStarted Nov 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Orlando, Florida, United States +20 more locations

Not Yet RecruitingPhase 411 miles

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

NCT06971939

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.

Macular Telangiectasia Type 2 (MacTel)

Neurotech Pharmaceuticals285 participantsStarted Aug 2025

La Jolla, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +30 more locations

TERMINATEDPhase 112 miles

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452

The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.

Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid Leukemia

Amgen141 participantsStarted Jun 2016

Duarte, California, United States • Sacramento, California, United States • Aurora, Colorado, United States +21 more locations

COMPLETED13 miles

MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

NCT06212466

A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.

Ischemic Heart DiseaseCoronary Microvascular DiseaseAngina+1 more

Genetesis Inc.136 participantsStarted Jun 2024

Gainesville, Florida, United States • Edgewood, Kentucky, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 216 miles

A Study in Participants With Non-cirrhotic NASH With Fibrosis

NCT05638737

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to directly benefit from treatment during this trial. Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

AstraZeneca112 participantsStarted Oct 2022

Chandler, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +62 more locations

COMPLETEDPhase 348 miles

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

NCT05259033

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries. Participants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls. At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Diabetes Mellitus, Type 2

Novo Nordisk A/S683 participantsStarted Apr 2022

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Sun City West, Arizona, United States +133 more locations

Enrolling By InvitationPhase 280 miles

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT06169397

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Pulmonary Sarcoidosis

Xentria, Inc.94 participantsStarted Mar 2024

Denver, Colorado, United States • Chicago, Illinois, United States • Greenville, North Carolina, United States +8 more locations

Active Not RecruitingPhase 380 miles

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

NCT06109649

The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.

Clinuvel, Inc.200 participantsStarted Oct 2023

Birmingham, Alabama, United States • Fresno, California, United States • Los Angeles, California, United States +27 more locations

COMPLETED190 miles

Observational Maternal COVID-19 Vaccination Study

NCT04826640

This is a prospective, observational study. During the study, pregnant women will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day and during the 7 days following the second vaccination using either identical web-based or paper diaries, depending on study participant preference. Maternal serum samples will be collected for antibody titers relevant to COVID-19 at time points that include: prior to vaccination, \~29 days post second vaccination, and at delivery. At Duke University, maternal and infant cord blood will be collected at delivery and analyzed for the same antibody titers. At other clinical sites, these delivery samples will only be collected if feasible. Pregnant women will be followed through 90 days postpartum. with comprehensive obstetric and neonatal outcomes obtained from medical record review.

Duke University146 participantsStarted May 2021

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Durham, North Carolina, United States +1 more locations

TERMINATEDPhase 2190 miles

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

COMPLETEDPhase 21068 miles

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957

To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy (RRT) on Day 28. The need for continued RRT at Day 28 will be defined as either dialysis in the past 3 days (Day 26, 27, or 28) or an eGFR on Day 28 \<10 mL/min/1.73 m2.

COVIDSevere Acute Respiratory SyndromeSars-CoV2+2 more

Arch Biopartners Inc.61 participantsStarted Oct 2020

San Diego, California, United States • Fort Lauderdale, Florida, United States • Shreveport, Louisiana, United States +4 more locations

RECRUITING1965 miles

AutoInflammatory Disease Alliance Registry (AIDA)

NCT05200715

Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic/multifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings. In this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.

Hereditary Autoinflammatory DiseasesSchnitzler SyndromeBehcet Syndrome+8 more

University of Siena3,500 participantsStarted Aug 2020

Algiers, Algeria • Boumerdas, Algeria • Adelaide, Australia +109 more locations

PreviousPage 208 of 863Next

in New York

Heart Diseasein New York